Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map.

Lu TT, Liu B, Ge L, Liu YL, Lu Y

International journal of obesity (2005)26 Jan 2025Cited by 3 (Europe PMC)

PMID39865161DOI10.1038/s41366-025-01719-3PepBankPUB-39865161

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study35

2 results from studies that gave the peptide. 2 results from people.

01HumanSystematic reviewSafety outcome
In reviewed people with overweight or obesity, notable adverse events were associated with liraglutide; the event types, signed effect and reference were unstated.
In plain wordsIn reviewed people with overweight/obesity, liraglutide was linked to notable side effects; event types and comparison were unspecified.
Peptide
Liraglutide
Outcome
Direction not reportedAdverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Notable AEs were associated with liraglutide, naltrexone/bupropion, semaglutide, and orlistat.
3 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Report a problemFND-3986516131
02HumanSystematic reviewSafety outcome
In reviewed people with overweight or obesity, notable adverse events were associated with semaglutide; the event types, signed effect and reference were unstated.
In plain wordsIn reviewed people with overweight/obesity, semaglutide was linked to notable side effects; event types and comparison were unspecified.
Peptide
Semaglutide
Outcome
Direction not reportedAdverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Notable AEs were associated with liraglutide, naltrexone/bupropion, semaglutide, and orlistat.
3 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Report a problemFND-3986516132

Studies that did not test the peptide alone33

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including liraglutide showed beneficial body weight outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including liraglutide showed beneficial body weight changes; their comparison was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3986516101
04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including semaglutide showed beneficial body weight outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including semaglutide showed beneficial body weight changes; their comparison was unstated.
Peptide
Semaglutide
Outcome
Direction not reportedBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3986516102
05HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including tirzepatide showed beneficial body weight outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including tirzepatide showed beneficial body weight changes; their comparison was unstated.
Peptide
Tirzepatide
Outcome
Direction not reportedBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3986516103
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including liraglutide showed beneficial weight loss outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including liraglutide showed beneficial weight loss changes; their comparison was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedWeight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3986516104
07HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including semaglutide showed beneficial weight loss outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including semaglutide showed beneficial weight loss changes; their comparison was unstated.
Peptide
Semaglutide
Outcome
Direction not reportedWeight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3986516105
08HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including tirzepatide showed beneficial weight loss outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including tirzepatide showed beneficial weight loss changes; their comparison was unstated.
Peptide
Tirzepatide
Outcome
Direction not reportedWeight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3986516106
09HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including liraglutide showed beneficial waist circumference outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including liraglutide showed beneficial waist circumference changes; their comparison was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedWaist circumference
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3986516107
10HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including semaglutide showed beneficial waist circumference outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including semaglutide showed beneficial waist circumference changes; their comparison was unstated.
Peptide
Semaglutide
Outcome
Direction not reportedWaist circumference
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3986516108
11HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including tirzepatide showed beneficial waist circumference outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including tirzepatide showed beneficial waist circumference changes; their comparison was unstated.
Peptide
Tirzepatide
Outcome
Direction not reportedWaist circumference
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3986516109
12HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including liraglutide showed beneficial body mass index outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including liraglutide showed beneficial body mass index changes; their comparison was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedBody mass index
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3986516110
13HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including semaglutide showed beneficial body mass index outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including semaglutide showed beneficial body mass index changes; their comparison was unstated.
Peptide
Semaglutide
Outcome
Direction not reportedBody mass index
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3986516111
14HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including tirzepatide showed beneficial body mass index outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including tirzepatide showed beneficial body mass index changes; their comparison was unstated.
Peptide
Tirzepatide
Outcome
Direction not reportedBody mass index
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3986516112
15HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including liraglutide showed beneficial total cholesterol outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including liraglutide showed beneficial total cholesterol changes; their comparison was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedTotal cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3986516113
16HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including semaglutide showed beneficial total cholesterol outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including semaglutide showed beneficial total cholesterol changes; their comparison was unstated.
Peptide
Semaglutide
Outcome
Direction not reportedTotal cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3986516114
17HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including tirzepatide showed beneficial total cholesterol outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including tirzepatide showed beneficial total cholesterol changes; their comparison was unstated.
Peptide
Tirzepatide
Outcome
Direction not reportedTotal cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3986516115
18HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including liraglutide showed beneficial triglycerides outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including liraglutide showed beneficial triglycerides changes; their comparison was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedTriglycerides
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3986516116
19HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including semaglutide showed beneficial triglycerides outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including semaglutide showed beneficial triglycerides changes; their comparison was unstated.
Peptide
Semaglutide
Outcome
Direction not reportedTriglycerides
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3986516117
20HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including tirzepatide showed beneficial triglycerides outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including tirzepatide showed beneficial triglycerides changes; their comparison was unstated.
Peptide
Tirzepatide
Outcome
Direction not reportedTriglycerides
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3986516118
21HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including liraglutide showed beneficial low-density lipoprotein cholesterol outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including liraglutide showed beneficial low-density lipoprotein cholesterol changes; their comparison was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedLow-density lipoprotein cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3986516119
22HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including semaglutide showed beneficial low-density lipoprotein cholesterol outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including semaglutide showed beneficial low-density lipoprotein cholesterol changes; their comparison was unstated.
Peptide
Semaglutide
Outcome
Direction not reportedLow-density lipoprotein cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3986516120
23HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including tirzepatide showed beneficial low-density lipoprotein cholesterol outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including tirzepatide showed beneficial low-density lipoprotein cholesterol changes; their comparison was unstated.
Peptide
Tirzepatide
Outcome
Direction not reportedLow-density lipoprotein cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3986516121
24HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including liraglutide showed beneficial high-density lipoprotein cholesterol outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including liraglutide showed beneficial high-density lipoprotein cholesterol changes; their comparison was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedHigh-density lipoprotein cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3986516122
25HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including semaglutide showed beneficial high-density lipoprotein cholesterol outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including semaglutide showed beneficial high-density lipoprotein cholesterol changes; their comparison was unstated.
Peptide
Semaglutide
Outcome
Direction not reportedHigh-density lipoprotein cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3986516123
26HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including tirzepatide showed beneficial high-density lipoprotein cholesterol outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including tirzepatide showed beneficial high-density lipoprotein cholesterol changes; their comparison was unstated.
Peptide
Tirzepatide
Outcome
Direction not reportedHigh-density lipoprotein cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3986516124
27HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including liraglutide showed beneficial blood pressure outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including liraglutide showed beneficial blood pressure changes; their comparison was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedBlood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3986516125
28HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including semaglutide showed beneficial blood pressure outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including semaglutide showed beneficial blood pressure changes; their comparison was unstated.
Peptide
Semaglutide
Outcome
Direction not reportedBlood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3986516126
29HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including tirzepatide showed beneficial blood pressure outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including tirzepatide showed beneficial blood pressure changes; their comparison was unstated.
Peptide
Tirzepatide
Outcome
Direction not reportedBlood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3986516127
30HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including liraglutide showed beneficial glycemic profile outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including liraglutide showed beneficial glycemic profile changes; their comparison was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedGlycemic profile
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3986516128
31HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including semaglutide showed beneficial glycemic profile outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including semaglutide showed beneficial glycemic profile changes; their comparison was unstated.
Peptide
Semaglutide
Outcome
Direction not reportedGlycemic profile
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3986516129
32HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In reviewed people with overweight or obesity, six pooled weight-management pharmacotherapies including tirzepatide showed beneficial glycemic profile outcomes; the exact reference was unstated.
In plain wordsIn people with overweight/obesity, pooled drugs including tirzepatide showed beneficial glycemic profile changes; their comparison was unstated.
Peptide
Tirzepatide
Outcome
Direction not reportedGlycemic profile
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile.
4 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
Summary · context
Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3986516130
33HumanNot a test of Liraglutide aloneSystematic reviewOther
In reviewed overweight/obesity populations, 101 of 115 associations (88%) across six pooled weight-management drugs were statistically significant and beneficial; this was not a patient responder rate.
In plain wordsIn reviewed overweight/obesity populations, 101 of 115 associations across six pooled weight-management drugs were statistically significant and beneficial.
Peptide
Liraglutide
Outcome
Not applicableStatistically significant beneficial associations
Study
n: not reported in source
Outcome group
Overall treatment effect · Whole body
Measurements
Statistically significant beneficial associations
101 associations
pooled six-drug umbrella synthesis
Total associations
115 associations
pooled six-drug umbrella synthesis
Statistically significant beneficial association proportion
88%
of115associations, not patients or a native-drug estimate
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes
3 context sentences(design, population, supporting numbers)
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3986516133
34HumanNot a test of Semaglutide aloneSystematic reviewOther
In reviewed overweight/obesity populations, 101 of 115 associations (88%) across six pooled weight-management drugs were statistically significant and beneficial; this was not a patient responder rate.
In plain wordsIn reviewed overweight/obesity populations, 101 of 115 associations across six pooled weight-management drugs were statistically significant and beneficial.
Peptide
Semaglutide
Outcome
Not applicableStatistically significant beneficial associations
Study
n: not reported in source
Outcome group
Overall treatment effect · Whole body
Measurements
Statistically significant beneficial associations
101 associations
pooled six-drug umbrella synthesis
Total associations
115 associations
pooled six-drug umbrella synthesis
Statistically significant beneficial association proportion
88%
of115associations, not patients or a native-drug estimate
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes
3 context sentences(design, population, supporting numbers)
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3986516134
35HumanNot a test of Tirzepatide aloneSystematic reviewOther
In reviewed overweight/obesity populations, 101 of 115 associations (88%) across six pooled weight-management drugs were statistically significant and beneficial; this was not a patient responder rate.
In plain wordsIn reviewed overweight/obesity populations, 101 of 115 associations across six pooled weight-management drugs were statistically significant and beneficial.
Peptide
Tirzepatide
Outcome
Not applicableStatistically significant beneficial associations
Study
n: not reported in source
Outcome group
Overall treatment effect · Whole body
Measurements
Statistically significant beneficial associations
101 associations
pooled six-drug umbrella synthesis
Total associations
115 associations
pooled six-drug umbrella synthesis
Statistically significant beneficial association proportion
88%
of115associations, not patients or a native-drug estimate
Source sentences
Summary
Overall, 101 statistically significant associations (88%) had beneficial outcomes
3 context sentences(design, population, supporting numbers)
Summary · context
Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included.
Summary · context
A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024.
Summary · context
The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3986516135

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map.

Summary

Results from this study35

Studies that did not test the peptide alone33

Version history

Subjects

Publication types

MeSH terms